The "Daily Deal" was in San Francisco -- and picked this up:
. . . .While Wyeth research chief Mikael Dolsten talked up his firm's pipeline and tried his best Tuesday morning to avoid any mention of Pfizer Inc., another megamerger participant -- Merck & Co. chief licensing officer Barbara Yanni, a fixture at industry partnering conferences -- had plenty to say about her firm's pending $41 billion takeover of Schering-Plough Corporation. She posted slides of the two firms' products, pipelines, and reminded the audience of Merck's wonderful reasons for the deal. She even joked about having to post not one but two pages of forward-looking statements. When you're the buyer, it's easier to speak freely, perhaps. Then again, Merck claims it's not really the buyer -- nudge, nudge, wink, wink -- in order to avoid losing (to Johnson & Johnson) Schering's shared rights to a rheumatoid arthritis drug over change-of-control issues. . . .
Heh. We shall see.
No comments:
Post a Comment